5 results about "XIAP" patented technology

The present disclosure provides compounds for inhibiting XIAP activity, pharmaceutical compositions comprising the compounds, and methods or uses of the compounds for treating diseases.

The invention belongs to the technical field of recombinant adeno-associated virus production, and discloses an rAAV plasmid system of a high-yield cytotoxic gene and an application of the rAAV plasmid system. The rAAV plasmid system of the high-yield cytotoxic gene comprises a transgenic plasmid, a packaging plasmid and an auxiliary plasmid, the helper plasmid comprises a gene sequence of an apoptosis inhibition factor xIAP. According to the present invention, the target auxiliary gene can be highly expressed during the production of the rAAV containing the cytotoxic gene, such that the production efficiency of the rAAV is effectively improved, and the technical effects of improving the druggability of the rAAV and reducing the production cost are achieved.

This invention provides a probe library and kit for detecting genetic risk gene mutations in viral infections, belonging to the field of gene detection technology. The probe library and kit designed in this invention achieve, for the first time, the simultaneous detection of all mutations in the following 51 genetic risk genes for viral infections: CARMIL2, CCL2, CD27, CD70, CIB1, CTPS1, CXCR4, CYBC1(C17orf62), DBR1, FCGR3A, FCHO1, ICAM1, IFIH1, IFNAR1, IFNAR2, IFNGR1, IFNGR2, IL10, IL10RA, IL10RB, IL... The probe library and kit of this invention contain 18BP, IRF3, IRF7, IRF9, MAGT1, LIG1, MCM2, NOS2, OAS1, POLR3A, POLR3C, POLR3F, PRKCD, RASGRP1, SH2D1A, STAT1, STAT2, TBK1, TICAM1, TLR3, TLR7, TLR8, TMC6, TMC8, TNFRSF9, TRAF1, TRAF2, TRAF3, TYK2, UNC93B1, and XIAP. This invention's probe library and kit can be used for detecting genetic variations in the risk of viral infection in clinical settings, assessing an individual's genetic risk of viral infection, and has broad application prospects.

The present invention relates to a bivalent bispecific monoclonal antibody (bbmAb), or a variant thereof, for use in treating or alleviating symptoms of a self-inflammation or disease based on CDC42 mutation or XIAP deficiency in a subject in need thereof.

The present disclosure relates to compounds that inhibit IAP (preferably XIAP, cIAP1, or cIAP2) protein, pharmaceutical compositions comprising the same and methods of using the IAP protein inhibitors in the treatment of diseases and conditions wherein inhibition of IAP protein provides a benefit.